|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA A Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA A
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
3
|
Colombo N, Carinelli S, Colombo A, Marini
C, Rollo D and Sessa C; ESMO Guidelines Working Group, : Cervical
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 23 (Suppl 7):vii27–vii32. 2012.
View Article : Google Scholar
|
|
4
|
Manzo-Merino J, Contreras-Paredes A,
Vázquez-Ulloa E, Rocha-Zavaleta L, Fuentes-Gonzalez AM and Lizano
M: The role of signaling pathways in cervical cancer and molecular
therapeutic targets. Arch Med Res. 45:525–539. 2014. View Article : Google Scholar
|
|
5
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar
|
|
6
|
Liang X, Liu Y, Zeng L, Yu C, Hu Z, Zhou Q
and Yang Z: miR-101 inhibits the G1-to-S phase transition of
cervical cancer cells by targeting Fos. Int J Gynecol Cancer.
24:1165–1172. 2014. View Article : Google Scholar
|
|
7
|
Cheung T, Leung J, Chung TK, Lam S, To K
and Wong Y: C-fos overexpression is associated with the
pathoneogenesis of invasive cervical cancer. Gynecol Obstet Invest.
43:200–203. 1997. View Article : Google Scholar
|
|
8
|
Dong P, Ihira K, Hamada J, Watari H,
Yamada T, Hosaka M, Hanley SJ, Kudo M and Sakuragi N: Reactivating
p53 functions by suppressing its novel inhibitor iASPP: A potential
therapeutic opportunity in p53 wild-type tumors. Oncotarget.
6:19968–19975. 2015. View Article : Google Scholar
|
|
9
|
Dong P, Xiong Y, Watari H, Hanley SJ,
Konno Y, Ihira K, Suzuki F, Yamada T, Kudo M, Yue J and Sakuragi N:
Suppression of iASPP-dependent aggressiveness in cervical cancer
through reversal of methylation silencing of microRNA-124. Sci Rep.
6:354802016. View Article : Google Scholar
|
|
10
|
Xiong Y, Sun F, Dong P, Watari H, Yue J,
Yu MF, Lan CY, Wang Y and Ma ZB: iASPP induces EMT and cisplatin
resistance in human cervical cancer through miR-20a-FBXL5/BTG3
signaling. J Exp Clin Cancer Res. 36:482017. View Article : Google Scholar
|
|
11
|
Romaine SP, Tomaszewski M, Condorelli G
and Samani NJ: MicroRNAs in cardiovascular disease: An introduction
for clinicians. Heart. 101:921–928. 2015. View Article : Google Scholar
|
|
12
|
Sun NX, Ye C, Zhao Q, Zhang Q, Xu C, Wang
SB, Jin ZJ, Sun SH, Wang F and Li W: Long noncoding RNA-EBIC
promotes tumor cell invasion by binding to EZH2 and repressing
E-cadherin in cervical cancer. PLoS One. 9:e1003402014. View Article : Google Scholar
|
|
13
|
Hu X, Schwarz JK, Lewis JS Jr, Huettner
PC, Rader JS, Deasy JO, Grigsby PW and Wang X: A microRNA
expression signature for cervical cancer prognosis. Cancer Res.
70:1441–1448. 2010. View Article : Google Scholar
|
|
14
|
Hattori H, Janky RS, Nietfeld W, Aerts S,
Madan Babu M and Venkitaraman AR: p53 shapes genome-wide and cell
type-specific changes in microRNA expression during the human DNA
damage response. Cell Cycle. 13:2572–2586. 2014. View Article : Google Scholar
|
|
15
|
Croessmann S, Formisano L, Kinch LN,
Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH,
Cristofanilli M, He J, et al: Combined blockade of activating ERBB2
mutations and ER results in synthetic lethality of ER+/HER2 mutant
breast cancer. Clin Cancer Res. 25:277–289. 2019. View Article : Google Scholar
|
|
16
|
Sanchez-Vega F, Hechtman JF, Castel P,
Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ,
et al: EGFR and MET amplifications determine response to HER2
inhibition in ERBB2-amplified esophagogastric cancer. Cancer
Discov. 9:199–209. 2019. View Article : Google Scholar
|
|
17
|
Ross JS, Fakih M, Ali SM, Elvin JA,
Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S,
et al: Targeting HER2 in colorectal cancer: The landscape of
amplification and short variant mutations in ERBB2 and ERBB3.
Cancer. 124:1358–1373. 2018. View Article : Google Scholar
|
|
18
|
Xiang L, Jiang W, Ye S, He T, Pei X, Li J,
Chan DW, Ngan HYS, Li F, Tao P, et al: ERBB2 mutation: A promising
target in non-squamous cervical cancer. Gynecol Oncol. 148:311–316.
2018. View Article : Google Scholar
|
|
19
|
Barceló F, Ortiz-Lombardia M, Martorell M,
Oliver M, Méndez C, Salas JA and Portugal J: DNA binding
characteristics of mithramycin and chromomycin analogues obtained
by combinatorial biosynthesis. Biochemistry. 49:10543–10552. 2010.
View Article : Google Scholar
|
|
20
|
Kennedy B and Torkelson JL: Long-term
follow-up of stage III testicular carcinoma treated with
mithramycin (Plicamycin). Med Pediatr Oncol. 24:327–328. 1995.
View Article : Google Scholar
|
|
21
|
Dutcher JP, Coletti D, Paietta E and
Wiernik PH: A pilot study of alpha-interferon and plicamycin for
accelerated phase of chronic myeloid leukemia. Leuk Res.
21:375–380. 1997. View Article : Google Scholar
|
|
22
|
Fernández-Guizán A, Mansilla S, Barceló F,
Barceló F, Vizcaíno C, Núñez LE, Morís F, González S and Portugal
J: The activity of a novel mithramycin analog is related to its
binding to DNA, cellular accumulation, and inhibition of Sp1-driven
gene transcription. Chem Biol Interact. 219:123–132. 2014.
View Article : Google Scholar
|
|
23
|
Choi ES, Nam JS, Jung JY, Cho NP and Cho
SD: Modulation of specificity protein 1 by mithramycin A as a novel
therapeutic strategy for cervical cancer. Sci Rep. 4:71622014.
View Article : Google Scholar
|
|
24
|
Rao M, Atay SM, Shukla V, Hong Y, Upham T,
Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, et al:
Mithramycin depletes specificity protein 1 and activates p53 to
mediate senescence and apoptosis of malignant pleural mesothelioma
cells. Clin Cancer Res. 22:1197–1210. 2016. View Article : Google Scholar
|
|
25
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:72015. View Article : Google Scholar
|
|
26
|
Wright AA, Howitt BE, Myers AP, Dahlberg
SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle
N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic
differences between adenocarcinomas and squamous cell carcinomas of
the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar
|
|
27
|
Benedet J, Pecorelli S, Ngan H and Hacker
NF: Staging classifications and clinical practice guidelines for
gynaecological cancers. Int J Gynecol Obstetr. 70:207–312. 2000.
View Article : Google Scholar
|
|
28
|
Gioia G, Werner B, Nydam D and Moroni P:
Validation of a mycoplasma molecular diagnostic test and
distribution of mycoplasma species in bovine milk among New York
State dairy farms. J Dairy Sci. 99:4668–4677. 2016. View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Dong P, Xiong Y, Watari H, Hanley SJ,
Konno Y, Ihira K, Yamada T, Kudo M, Yue J and Sakuragi N: MiR-137
and miR-34a directly target Snail and inhibit EMT, invasion and
sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer
Res. 35:1322016. View Article : Google Scholar
|
|
31
|
Ihira K, Dong P, Xiong Y, Watari H, Konno
Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, et al: EZH2
inhibition suppresses endometrial cancer progression via
miR-361/Twist axis. Oncotarget. 8:13509–13520. 2017. View Article : Google Scholar
|
|
32
|
Hsiao YH, Hsieh MJ, Yang SF, Chen SP, Tsai
WC and Chen PN: Phloretin suppresses metastasis by targeting
protease and inhibits cancer stemness and angiogenesis in human
cervical cancer cells. Phytomedicine. 62:1529642019. View Article : Google Scholar
|
|
33
|
Hu Y, Ma Y, Liu J, Cai Y, Zhang M and Fang
X: LINC01128 expedites cervical cancer progression by regulating
miR-383-5p/SFN axis. BMC Cancer. 19:1–11. 2019. View Article : Google Scholar
|
|
34
|
Lv Y, Cang W, Li Q, Liao X, Zhan M, Deng
H, Li S, Jin W, Pang Z, Qiu X, et al: Erlotinib overcomes
paclitaxel-resistant cancer stem cells by blocking the
EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer.
Oncogenesis. 8:702019. View Article : Google Scholar
|
|
35
|
Han SA, Jang JH, Won KY, Lim SJ and Song
JY: Prognostic value of putative cancer stem cell markers (CD24,
CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Pathol Res Pract. 213:956–963. 2017. View Article : Google Scholar
|
|
36
|
Mizukami T, Kamachi H, Mitsuhashi T,
Tsuruga Y, Hatanaka Y, Kamiyama T, Matsuno Y and Taketomi A:
Immunohistochemical analysis of cancer stem cell markers in
pancreatic adenocarcinoma patients after neoadjuvant
chemoradiotherapy. BMC Cancer. 14:6872014. View Article : Google Scholar
|
|
37
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar
|
|
38
|
Siegel PM, Ryan ED, Cardiff RD and Muller
WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3
are involved in the induction of mammary tumors in transgenic mice:
Implications for human breast cancer. EMBO J. 18:2149–2164. 1999.
View Article : Google Scholar
|
|
39
|
Zhou BP, Hu MC, Miller SA, Yu Z, Xia W,
Lin SY and Hung MC: HER-2/neu blocks tumor necrosis factor-induced
apoptosis via the Akt/NF-kappaB pathway. J Biol Chem.
275:8027–8031. 2000. View Article : Google Scholar
|
|
40
|
Prigent SA and Gullick WJ: Identification
of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and
SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831–2841.
1994. View Article : Google Scholar
|
|
41
|
Vasudevan KM, Barbie DA, Davies MA,
Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P,
Kim SY, et al: AKT-independent signaling downstream of oncogenic
PIK3CA mutations in human cancer. Cancer Cell. 16:21–32. 2009.
View Article : Google Scholar
|
|
42
|
Bonazzoli E, Cocco E, Lopez S, Bellone S,
Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, et
al: PI3K oncogenic mutations mediate resistance to afatinib in
HER2/neu overexpressing gynecological cancers. Gynecol Oncol.
153:158–164. 2019. View Article : Google Scholar
|
|
43
|
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto
T, Kato S and Miyazono K: Modulation of microRNA processing by p53.
Nature. 460:529–533. 2009. View Article : Google Scholar
|
|
44
|
Dong P, Xiong Y, Hanley SJ, Yue J and
Watari H: Musashi-2, a novel oncoprotein promoting cervical cancer
cell growth and invasion, is negatively regulated by p53-induced
miR-143 and miR-107 activation. J Exp Clin Cancer Res. 36:1502017.
View Article : Google Scholar
|
|
45
|
Cousin S, Khalifa E, Crombe A, Laizet Y,
Lucchesi C, Toulmonde M, Le Moulec S, Auzanneau C, Soubeyran I and
Italiano A: Targeting ERBB2 mutations in solid tumors: Biological
and clinical implications. J Hematol Oncol. 11:862018. View Article : Google Scholar
|
|
46
|
Breyer J, Wirtz RM, Laible M, Schlombs K,
Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, et
al: ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade
of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch.
469:547–552. 2016. View Article : Google Scholar
|
|
47
|
Ursini-Siegel J, Schade B, Cardiff RD and
Muller WJ: Insights from transgenic mouse models of ERBB2-induced
breast cancer. Nat Rev Cancer. 7:389–397. 2007. View Article : Google Scholar
|
|
48
|
Di Cosimo S and Baselga J: Targeted
therapies in breast cancer: Where are we now? Eur J Cancer.
44:2781–2790. 2008. View Article : Google Scholar
|
|
49
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View Article : Google Scholar
|
|
50
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar
|
|
51
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar
|
|
52
|
Hurtado A, Holmes KA, Geistlinger TR,
Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S and
Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2
determines response to tamoxifen. Nature. 456:663–666. 2008.
View Article : Google Scholar
|
|
53
|
Demidov ON, Kek C, Shreeram S, Timofeev O,
Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK
pathway in Wip1-dependent regulation of ErbB2-driven mammary gland
tumorigenesis. Oncogene. 26:2502–2506. 2007. View Article : Google Scholar
|
|
54
|
Daly JM, Jannot CB, Beerli RR, Graus-Porta
D, Maurer FG and Hynes NE: Neu differentiation factor induces ErbB2
down-regulation and apoptosis of ErbB2-overexpressing breast tumor
cells. Cancer Res. 57:3804–3811. 1997.
|
|
55
|
Wang Y, Zhang X, Chao Z, Kung HF, Lin MC,
Dress A, Wardle F, Jiang BH and Lai L: MiR-34a modulates ErbB2 in
breast cancer. Cell Biol Int. 41:93–101. 2017. View Article : Google Scholar
|
|
56
|
He XH, Zhu W, Yuan P, Jiang S, Li D, Zhang
HW and Liu MF: miR-155 downregulates ErbB2 and suppresses
ErbB2-induced malignant transformation of breast epithelial cells.
Oncogene. 35:6015–6025. 2016. View Article : Google Scholar
|
|
57
|
Malek A, Núñez LE, Magistri M, Brambilla
L, Jovic S, Carbone GM, Morís F and Catapano CV: Modulation of the
activity of Sp transcription factors by mithramycin analogues as a
new strategy for treatment of metastatic prostate cancer. PLoS One.
7:e351302012. View Article : Google Scholar
|
|
58
|
Wang L, Guan X, Zhang J, Jia Z, Wei D, Li
Q, Yao J and Xie K: Targeted inhibition of Sp1-mediated
transcription for antiangiogenic therapy of metastatic human
gastric cancer in orthotopic nude mouse models. Int J Oncol.
33:161–167. 2008.
|
|
59
|
Haupt S, Raghu D and Haupt Y: Mutant p53
drives cancer by subverting multiple tumor suppression pathways.
Front Oncol. 6:122016. View Article : Google Scholar
|
